Fluidigm Releases CFTR Next-Generation Sequencing Library Prep Assay for Use With the Juno System
Cystic fibrosis (CF) is a complex, multisystem disease that is caused by mutations in the CFTR gene and affects over 70,000 individuals worldwide. With more than 2,000 variants identified in the CFTR gene, NGS offers a more comprehensive approach to CFTR genetic analysis than traditional genotyping methods. Current NGS targeted sequencing library prep workflows, however, can be very costly and labor-intensive for a molecular laboratory.
Developed for research use with the Juno™ system, the Advanta CFTR NGS Library Prep Assay automates the target enrichment of CFTR variants from each of the gene’s 27 exons and selected intronic regions using proven microfluidics technology. Providing a significant savings opportunity in cost per sample, the workflow substantially reduces hands-on time and conserves precious reagents by reducing reactions to nanoliter scale.
With the capacity to produce from 48 to 1,500 or more NGS libraries each week from DNA derived from blood, saliva or buccal swabs, this Advanta assay offers simplified scalability to meet customer needs. Each integrated microfluidic circuit (IFC) is also provided with open inlets to simplify the addition of new assays over time.
“This new product is representative of an expanding menu of high-value genetic assays we are developing for use with
We use our website (www.fluidigm.com), corporate Twitter account (@fluidigm),
Forward-Looking Statement for
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the anticipated benefits of newly introduced products and development of additional products. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to risks relating to uncertainties in contractual relationships and international regulated markets; challenges inherent in developing, manufacturing, launching, marketing, and selling new products; the uncertain regulatory environment; potential product performance and quality issues; intellectual property risks; competition; interruptions or delays in the supply of components or materials for, or manufacturing of,
Senior Director, Marketing
650 737 4190
Source: Fluidigm Corporation